STOP Study: Effectiveness of Zyban in a Clinical Population

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Despite the significant health, social and economic costs of cigarette smoking, 17% of Ontarians still currently smoke. Use of smoking cessation pharmacotherapy such as Zyban (bupropion HCl) has been shown to double quit rates but such medications are under-utilized by smokers attempting to quit. It has been suggested that the high price of pharmacotherapy may act as a barrier to accessing such treatment.The main objective of this study is to evaluate the methods and effectiveness of providing smokers who want to quit with 8 weeks of free Zyban in combination with smoking cessation counselling through family health teams and community health centres across the province.

Hypothesis: Ontario smokers who receive 8-weeks of free bupropion in combination with brief counselling will have higher smoking cessation rates than the standard population cessation rates.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Collaborator: Ontario Ministry of Health and Long Term Care
• Treatments: Bupropion

Criteria

Inclusion Criteria:

• Ontario resident

• 18 years of age or older

• Current daily cigarette smoker who smokes 10 or more cigarettes per day and has smoked > 100 cigarettes in their lifetime

• Want to quit smoking cigarettes within 30 days of assessment

• Willingness and capacity to give written informed consent and to comply with study protocol

Exclusion Criteria:

• Enrollment in any of the STOP Study NRT models in the past 6 months

• Currently receiving Wellbutrin SR or any medication containing bupropion hydrochloride

• Current seizure disorder or history of seizures

• Current or prior diagnosis of bulimia or anorexia nervosa

• Current diagnosis of bipolar disorder

• History of head trauma

• Allergy or sensitivity to Zyban, Wellbutrin or bupropion

• Undergoing abrupt withdrawal from alcohol, benzodiazepines or other sedatives

• Currently taking monoamine oxidase (MAO) inhibitors, or thioridazine

• Pregnant or breastfeeding or at risk of becoming pregnant

• Central nervous system (CNS) tumor

• Severe hepatic impairment